NCT07403201 The Effect of Therapy Combination in PCOS With Dlbs 3233
| NCT ID | NCT07403201 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Inlacinpenelitian |
| Condition | Polycystic Ovary Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2021-12-15 |
| Primary Completion | 2026-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 90 participants in total. It began in 2021-12-15 with a primary completion date of 2026-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The effect of combination therapy dlbs 3233 and clomifen citrate vs clomifen citrate on homa ir, maturation follicle, and menstrual cycle in PCOS cases at Muhammadiyah Asri Medical Center Hospital
Eligibility Criteria
Inclusion Criteria: * married agree to join this research Exclusion Criteria: * dis agree to join research
Contact & Investigator
UMY Yogyakarta
STUDY DIRECTOR
muhammadiyah university of yogyakarta
Frequently Asked Questions
Who can join the NCT07403201 clinical trial?
This trial is open to female participants only, up to 45 Years, studying Polycystic Ovary Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07403201 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07403201 currently recruiting?
Yes, NCT07403201 is actively recruiting participants. Contact the research team at prastikacandra13@gmail.com for enrollment information.
Where is the NCT07403201 trial being conducted?
This trial is being conducted at Yogyakarta, Indonesia.
Who is sponsoring the NCT07403201 clinical trial?
NCT07403201 is sponsored by Inlacinpenelitian. The principal investigator is UMY Yogyakarta at muhammadiyah university of yogyakarta. The trial plans to enroll 90 participants.